| Patient | Fannie Lou Hamer |
|---|---|
| Date of birth | 1976-10-06 |
| Identifiers | MRN HR-ML031-SYN; SSN (made up) 000-31-2479 |
| Document date | 2026-10-19 |
| Author | Lorraine Batiste-Hill, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Seven-month review: A1c, urine albumin, kidney function, seasonal and age-50 vaccines, screening results, and plans for the winter. [S]
Mrs. Hamer returns five weeks after her preventive visit; she turned 50 this month. Her mammogram two weeks ago showed no abnormality, and her stool test, HIV and hepatitis C tests were negative. She went to the mammogram with the community health worker and said the technologist explained every step. Her home readings average 126/78. She takes metformin 1,500 mg with her evening meal without stomach trouble and has had no low blood sugar. Food and heating are covered for the winter, and the van has brought her to every visit. She asked about the vaccines due this autumn and what each one is for. [S]
| Element | Detail |
|---|---|
| Screening | Mammogram normal; stool test, HIV and hepatitis C negative |
| Home blood pressure | Average 126/78 |
| Metformin | 1,500 mg, well tolerated |
| Vaccines | Influenza, COVID-19 and zoster discussed |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or weight gain |
| Cardiovascular | Negative | No ankle swelling |
| Gastrointestinal | Negative | No stomach upset |
| Genitourinary | Negative | No burning or genital itching |
| Psychiatric | Negative | Mood steady |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin extended-release 500 mg oral tablet, one tablet with the evening meal for one week, then two tablets with the evening meal | Two tablets with the evening meal (after one week of one tablet) | Oral route | 2026-03-09 to 2026-07-13 | completed | S |
| Metformin extended-release 500 mg oral tablet, three tablets with the evening meal | Three tablets with the evening meal | Oral route | 2026-07-13 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-09 | active | S |
| Amlodipine 5 mg and benazepril 20 mg combined oral capsule, one capsule daily | One capsule daily | Oral route | 2026-03-23 | active | S |
| Dapagliflozin 10 mg oral tablet, one tablet daily; stop on days of vomiting, diarrhea or not eating, and before surgery | One tablet daily, with sick-day rules | Oral route | 2026-03-23 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-19 | Body height | 163 | cm | S |
| 2026-10-19 | Body weight | 90 | kg | S |
| 2026-10-19 | Body mass index (BMI) [Ratio] | 33.9 | kg/m2 | S |
| 2026-10-19 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-10-19 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-10-19 | Heart rate | 74 | /min | S |
| 2026-10-19 | Respiratory rate | 16 | /min | S |
| 2026-10-19 | Body temperature | 36.7 | Cel | S |
| 2026-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-19 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.9 | % | Below 5.7% is normal; 6.5% or higher is diabetes; goal below 7% for her | High | S |
| 2026-10-19 | Albumin/Creatinine [Mass Ratio] in Urine | 41 | mg/g | Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2) | High | S |
| 2026-10-19 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-19 | Creatinine [Mass/volume] in Serum or Plasma | 1 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-10-19 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 69 | mL/min/{1.73_m2} | 90 or higher is normal; 60 to 89 is mildly decreased (G2) | Low | S |
| 2026-10-19 | Accountable health communities (AHC) health-related social needs screening (HRSN) tool | 1 | {score} | S |
Vital signs recorded on 2026-10-19; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Consent and chaperone | Each vaccine, the blood draw, urine sample and examination explained and agreed; she accepted all three vaccines; female nurse present |
| General | Well; blood pressure 124/76, pulse 74; weight 90.0 kg |
| Cardiovascular | Regular rhythm; no ankle swelling |
| Feet | Inspected with her agreement: no ulcers |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Type 2 diabetes with hyperglycemia, newly diagnosed: A1c 8.6% and random glucose 238 mg/dL with thirst and frequent urination; synthetic modern episode linked to the diabetes documented in her later life | active | confirmed | E11.65 | S — Synthetic modern diagnosis; diabetes is documented only at the end of her life. |
| Elevated blood pressure at intake (164/98 mmHg), without a diagnosis of hypertension; home readings for one week to confirm | resolved | confirmed | R03.0 | S — Synthetic presenting finding, superseded by the confirmed diagnosis at two weeks. |
| Albumin in the urine (urine albumin-to-creatinine ratio 88 mg/g) and eGFR 73, in a woman whose kidneys were injured in a beating years ago; to be repeated and investigated | resolved | confirmed | R80.9 | S — Synthetic presenting finding, superseded by the kidney diagnosis at two weeks; the old kidney injury is documented. |
| Hypertension, stage 2, confirmed by home readings (average 152/94 mmHg), with chronic kidney disease; synthetic modern episode linked to the hypertension reported in her later life | active | confirmed | I12.9 | S — Synthetic modern diagnosis; hypertension is reported only at the end of her life. |
| Chronic kidney disease G2 A2 (eGFR 73, albumin-to-creatinine ratio 88 to 96 mg/g), with a small, scarred right kidney on ultrasound consistent with old injury; diabetes and high blood pressure likely contribute | active | confirmed | N18.2 | S — Synthetic kidney findings anchored to the documented permanent kidney damage. |
| Type 2 diabetes with diabetic chronic kidney disease (coded with the kidney disease by convention) | active | confirmed | E11.22 | S — Synthetic modern coding. |
| Food insecurity: food runs out before the end of most months | active | confirmed | Z59.41 | S — Synthetic social need found on the screen. |
| Transportation insecurity: no car; the health center is a long drive away and rides are hard to arrange | active | confirmed | Z59.82 | S — Synthetic social need anchored to her rural Delta home. |
| Hyperlipidemia: LDL 146 mg/dL | active | confirmed | E78.5 | S — Synthetic laboratory finding. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Consent and chaperone for every examination, test and procedure | Every visit | Completed today | Each vaccine and test explained and agreed |
| Examination | Clinic blood pressure (seated, two readings, large cuff) | Every visit | Completed today | 124/76 |
| Self-management | Home blood pressure readings | Seven days to confirm the diagnosis; then twice a week, and daily for a week after any change | Completed today | Average 126/78 |
| Examination | Weight and BMI | Every visit | Completed today | 90.0 kg, down 3 kg since intake |
| Laboratory | Hemoglobin A1c | Every 3 months until at goal, then every 6 months | Completed today | 6.9% |
| Laboratory | Urine albumin-to-creatinine ratio | Repeat to confirm; 3 to 6 months after a treatment change; then every 6 months while moderately increased | Completed today | 41 mg/g |
| Laboratory | Potassium, creatinine and eGFR | One to two weeks after starting an ACE inhibitor, then every 6 months (more often with changes) | Completed today | Potassium 4.5 mmol/L; creatinine 1.00 mg/dL, eGFR 69 |
| Laboratory | Lipid panel | 4 to 12 weeks after starting a statin, then yearly | Up to date | LDL 80 in May; yearly panel at one year |
| Imaging | Diabetic eye examination (retinal photographs) | At diagnosis, then every 1 to 2 years if no retinopathy | Up to date | No retinopathy in May |
| Examination | Foot inspection, and comprehensive foot examination | Inspection every visit; comprehensive examination yearly | Completed today | Inspection normal; comprehensive examination due at one year |
| Laboratory | Vitamin B12 on metformin | Periodically, about yearly | Due | At the one-year visit |
| Medication safety | Medicine safety: low blood sugar, sick-day rules, genital infections, cough, swelling, adherence and cost | Every visit | Completed today | No side effects; 90-day supplies arranged for winter |
| Medication safety | Influenza, COVID-19 and recombinant zoster vaccines | Influenza and COVID-19 each autumn; zoster from 50, two doses 2 to 6 months apart | Completed today | All three given after she agreed; zoster dose 2 in two to six months |
| Survey | Depression screen (PHQ-9) | At intake, then every 6 to 12 months | Up to date | PHQ-9 3 three months ago; PHQ-2 0 at the preventive visit |
| Survey | Social needs screen (AHC-HRSN) and resources | At intake, then every few months while needs are open | Completed today | One core need positive (transportation on some days) |
| Referral | Nephrology review | At diagnosis; then by telehealth if albumin stays raised | Due | Telehealth review in the new year because albumin remains moderately increased |
Goal progress:
Immunizations given today: Influenza vaccine, inactivated, this season; COVID-19 vaccine, mRNA, this season; Recombinant zoster vaccine, dose 1 of 2 [S]
Guideline basis: Introduction and Methodology: Standards of Care in Diabetes-2026 (2026); 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026); 1. Improving Care and Promoting Health in Populations: Standards of Care in Diabetes-2026 (2026); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, hypertension, diabetes type 2, hyperlipidemia, chronic kidney disease and depression monographs (2026); Trauma-Informed Care in Behavioral Health Services (Treatment Improvement Protocol 57) (2014); Code of Medical Ethics Opinion 2.1.1: Informed Consent (2026); The Accountable Health Communities Health-Related Social Needs Screening Tool (2017); Adult Immunization Schedule by Age (2026); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Telehealth nephrology review in the new year. Review in three months, or by phone if travel fails; second zoster dose in two to six months. Call for dizziness, vomiting that stops her drinking, or any new symptom. [S]